Loading...
Please wait, while we are loading the content...
Similar Documents
Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB‐IIIC vs stage IV epithelial ovarian cancer after primary surgery
| Content Provider | Scilit |
|---|---|
| Author | Sørensen, Sarah M. Schnack, Tine H. Høgdall, Claus |
| Copyright Year | 2018 |
| Description | Journal: Acta Obstetricia et Gynecologica Scandinavica Introduction The objective of this study was to determine the impact of residual disease (RD) size, type (carcinomatosis/tumor mass/both) and location (upper/lower abdominal/both) on overall survival in women with FIGO stage IIIB‐IIIC vs. stage IV epithelial ovarian cancer who underwent primary debulking surgery. Material and methods 2092 women diagnosed with advanced epithelial ovarian cancer undergoing primary debulking surgery in Denmark during 2005‐2016 were identified in the Danish Gynecological Cancer Database. Impact of RD size, type and location were evaluated using uni‐ and multivariate analyses. Results Complete cytoreduction (RD=0) was achieved in 47.3% and 38.4% of cases in stage IIIB‐IIIC and IV epithelial ovarian cancer, respectively. A benefit in overall survival was observed in patients with RD=0 as compared to patients with residual disease, and among patients with RD ≤1cm as compared to RD >2cm in both stage IIIB‐IIIC and stage IV patients in multivariate analyses. Multivariate analyses showed an inferior overall survival for women with both residual carcinomatosis and residual tumor mass compared to residual tumor mass or residual carcinomatosis only for stage IIIB‐IIIC and IV patients, and an inferior overall survival for RD located in both upper and lower abdomen as compared to RD in the upper abdomen only in stage IIIB‐IIIC patients. Conclusions Our results confirm the positive prognostic impact of both complete cytoreduction and RD ≤1cm in stage IIIB‐IIIC as well as stage IV epithelial ovarian cancer. Stage IV patients do benefit from cytoreductive surgery and should be considered for primary debulking surgery, if RD=0 can be expected upfront. This article is protected by copyright. All rights reserved. |
| Ending Page | 43 |
| Starting Page | 34 |
| ISSN | 00221295 |
| e-ISSN | 16000412 |
| DOI | 10.1111/aogs.13453 |
| Journal | Acta Obstetricia et Gynecologica Scandinavica |
| Issue Number | 1 |
| Volume Number | 98 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2019-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Acta Obstetricia et Gynecologica Scandinavica Obstetrics and Gynecology Ovarian Cancer Cytoreductive Surgery Primary Debulking Surgery Residual Disease Residual Tumor |
| Content Type | Text |
| Resource Type | Article |
| Subject | Obstetrics and Gynecology |
